A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA® (pegloticase) (MIRROR Randomized Controlled Trial [RCT])

    Not Recruiting
Updated on 22 June 2022


The purpose of this study is to obtain information on the safety, tolerability and effectiveness of administering an immunosuppressive therapy (Methotrexate) (MTX) in combination with KRYSTEXXA (also called pegloticase) to prevent immunogenicity against pegloticase, in adults with uncontrolled gout.
In the current study, MTX will be evaluated for its ability to reduce anti drug antibodies against pegloticase that lead to loss of response and that are associated with AEs including IRs. 
This may allow you to receive a longer course of therapy or repeated courses of therapy, as needed.


  • 52wks
  • 36 visits
  • 26 Infusions Q2wks
  • Infusions are 4-5 hrs in length.

Condition Gout (Hyperuricemia)
Clinical Study IdentifierTX230589
Last Modified on22 June 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note